Recro Pharma Inc represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Recro Pharma is dedicated to developing and delivering high-quality medications to patients in need. The company's corporate philosophy emphasizes delivering innovative drug solutions that meet the highest standards of safety and efficacy. Recro Pharma is committed to conducting business ethically and maintaining strong relationships with healthcare professionals, patients, and stakeholders. Through its dedication to research and development, Recro Pharma aims to improve patient outcomes and enhance the quality of life for individuals around the world.

Recro Pharma Inc primarily operates in the United States.

Recro Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for its lead product, IV meloxicam, a non-opioid pain management option. They also secured a licensing agreement for IV meloxicam with Baudax Bio Inc and expanded its use to multiple surgical indications. In addition, Recro Pharma Inc successfully completed a Phase III clinical trial for a new treatment option targeting postoperative pain. The company continues to focus on research and development to provide innovative solutions for patients and healthcare professionals. Recro Pharma Inc's achievements highlight their commitment to advancing pain management and improving patient outcomes.

Recro Pharma Inc is a pharmaceutical company with a rich history and background. Established in 2007, the company is based in Malvern, Pennsylvania. Recro Pharma specializes in developing and commercializing innovative therapies for acute care settings. They focus on creating non-opioid pain management solutions, addressing the growing need for safer and more effective alternatives. The company's dedicated team of scientists and researchers work diligently to provide patients with advanced pharmaceutical products. Recro Pharma's commitment to excellence and dedication to improving patient outcomes has earned them a reputable position in the pharmaceutical industry.

The main competitors of Recro Pharma Inc in the market include companies such as Mallinckrodt Pharmaceuticals, Pfizer Inc, and Amneal Pharmaceuticals.

Recro Pharma Inc is primarily active in the pharmaceutical industry.

Recro Pharma Inc operates as a specialty pharmaceutical company. Its business model involves developing and commercializing innovative products for hospital and ambulatory care settings. Recro Pharma focuses on therapies that address pain management, acute care, and other medical needs. By leveraging its expertise in formulation and manufacturing, the company aims to provide advanced solutions to healthcare professionals and patients. With a commitment to delivering high-quality pharmaceuticals, Recro Pharma Inc continues to contribute to the improvement of patient outcomes and enhance medical treatment options.

مُعامل القيمة السوقية إلى الأرباح لـ Societal CDMO هو ؜-١١٫٤٣.

مُعامِل القيمة إلى المبيعات Societal CDMO هو ١٫٠٨.

نقاط جودة AlleAktien لـ Societal CDMO هي 3/10.

المتوقعة Societal CDMO الإيرادات هي ٩٦٫٨٢ مليون. USD.

صافي الربح المتوقعة Societal CDMO هو ؜-٩٫١٦ مليون. USD.

Recro Pharma Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative drugs to improve the health and well-being of patients worldwide. The company has three main divisions: Acute Care, Contract Development and Manufacturing Organization (CDMO), and Healthcare. Within the Acute Care division, the company has a portfolio of pain treatment drugs, including intravenous (IV) acetaminophen injections, methoxyflurane inhalers, and sublingual sufentanil tablets. The CDMO division offers manufacturing services for customers in the biotechnology and pharmaceutical industries. These services include process development and optimization, clinical and commercial manufacturing, stability studies, and quality assurance services. Recro Pharma's Healthcare division focuses on developing products to enhance patient care and safety. For example, the company is currently developing a novel nasal spray for the treatment of severe opioid overdoses. Recro Pharma relies on collaboration with partners and acquisitions of companies that complement its capabilities and processes necessary to create new solutions in the pharmaceutical products and services field. For example, the company was acquired by Alkermes plc in 2015 to acquire specialized formulation expertise and production capacity to complement its own resources. Recro Pharma's business model is based on focusing on continuous improvement of treatment options and patient care through innovative and effective drugs and services that are at the forefront of technology. The company intends to expand its drug development platform through technology partnerships, licensing of intellectual property, and acquisitions of companies to bring future products to market faster and more effectively. Overall, Recro Pharma has become a significant player in the pharmaceutical industry, catering to the needs of physicians, patients, and OEMs worldwide. Recro Pharma offers a wide range of innovative drugs and services that contribute to better healthcare and higher patient satisfaction.

يوزع Societal CDMO أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Societal CDMO في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـSocietal CDMO هو US75629F1093.

رمز WKN لـ Societal CDMO هو A1XFAV.

الرمز المُختصر لـ Societal CDMO هو SCTL.

خلال آخر 12 شهراً، دفعت Societal CDMO توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Societal CDMO خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Societal CDMO هي .

Societal CDMO يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Societal CDMO دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Societal CDMO يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Societal CDMO المُعلن عنها في ١١‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١١‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١١‏/٨‏/٢٠٢٤.

في العام 2023، وزعت Societal CDMO 0 USD كأرباح أسهم.

يتم توزيع أرباح Societal CDMO بالعملة USD.